It's a far cry from what people were saying two years ago. Reuters:
Some analysts have said Pristiq could post annual sales of up to $2 billion, if approved.That ain't happening. Leerink Swann estimates the drug earned sales of $67 million in 2008 and may get $260 million 2009. Those sales came after an ad campaign that compared depressed people to wind-up dolls (pictured).
There are three things wrong with Pristiq, according to observers. First, it's a blatant patent extender. Even the drug's developer -- Dr. Michael Liebowitz, the Columbia University psychiatrist who led the major Pristiq trials -- isn't impressed with it, noted Daniel Carlat:
Pristiq, he said, "is another SNRI -- it is not a revolutionary drug."Second, it generated a lot of adverse event reports in a short period of time, per Phil Dawdy, including 17 successful suicides.
And, Dawdy adds, the drug has withdrawal symptoms that people don't like.
Here's a bulletin board for people taking Pristiq. As you can see, patients don't seem impressed.
- Wyeth's Troubles: Ghostwriting to Be Revealed; Centrum Sales Weak
- Wyeth Q2: Ah! So That's Why Pfizer's Buying This Company
- Pfizer Offered $53 a Share for Wyeth; Wyeth Failed to Say Yes
- Wyeth, in Autism Case, Again Stars in Preemption Issue at Supreme Court
- Pfizer's Jet Sale: Downsizing or Upscaling? Wyeth Brings Its Own
- Wyeth's Own Vendors Gathered Evidence of Alleged Protonix Pricing Scam
- A Look Inside Pfizer's Corporate Jets, Now Up for Sale
- Wyeth CEO Got 69% Pay Raise; Was "Required" to Use Helicopter; Plus $24 Million Pfizer Sale Bonus